PDA Task Force for Single Use Systems
|
|
- Abigail Hoover
- 5 years ago
- Views:
Transcription
1 PDA Task Force for Single Use Systems Robert Repetto- Chairman Pfizer Morten Munk- Co-Chair CMC Biologics April, 2011 PDA Annual Meeting, San Antonio, Texas 1
2 2
3 What is a Single Use System?? 3
4 Technical Report (TR) on Single Use System (SUS) Support implementation of SUS A guide, listing the areas to consider Easy and fast to read Build on the current best practice Address regulatory aspects Address technical aspects Written by suppliers, users and regulatory bodies 4
5 PDA s Goals for Technical Reports PDA TR s should reflect a global perspective and are educational documents that are based in sound science and discuss meaningful studies and practical applications of the science They should include, not just the How s, but the Why s PDA TR s are points to consider documents; therefore, current and applicable references should be used wherever possible to give further detail and/or support concepts presented PDA Technical Reports are not intended to set standards 5
6 Approach to the PDA Technical Document Who are our Customers? Industry End Users Regulators Suppliers PDA Scientific Approval Board What do they want from this report? An understanding of Key Principles and Concepts for selection, use and qualification/validation of Single Use Systems Breath of knowledge to enable people at various levels in an organization to make effective decisions relating to Single Use Systems 6
7 PDA Single Use Systems Task Force Representatives from US and Europe Regulatory, US and Europe Biopharmaceuticals Vaccines Gene Therapy Small Molecules Industry Suppliers BPSA (Bio-Process Systems Alliance) Supplier 32% Regulator 5% Europe 29% Enabler 11% US 71% End Users 63% 7
8 Bill Hartzel Chris Smalley Christian Julien Duncan Low Eberhard Bill, Ph.D. Eric Isberg Ingrid Markovic James Robinson Jeff Carter, Ph.D Jerold Martin Michael Kraich, Ph.D. Morten Munk Co-Chair Niels Guldager Paul Priebe Rich Levy Robert Repetto Chair Robert Shaw Robin Alonso Russell Wong Stephen Brown Catalent / Formerly Arkema Inc. Merck Meissner Filtration Amgen Boehringer Ingelheim GmbH & Co. Computype, Inc / Formerly Thermo Fisher FDA Lachman Consultant Services, Inc. GE Healthcare Pall Life Sciences Boehringer Ingelheim GmbH & Co. CMC Biologics NNE Pharmaplan Sartorius Stedim Biotech PDA Pfizer Ark Therapeutics Genentech Bayer Healthcare Vivalis 8
9 PDA SUS 2011 Timeline January March April June Sept 1/20 F2F PDA SUS Work Shop SAB Section Reviews Tech Writing 2 nd tech edit Internal Review Tech Writing Finalize Draft SUS Survey External Review Tech Writing Finalize Report
10 Introduction Introduce QRM and QbD as a philosophical basis of document Flexible guidance providing concepts and key considerations so the reader can ask the right questions, and make the best decision for their individual situation Present guidance so an organizations can make the road map that suits them best. Partnership between Supplier and End User 10
11 Asking the Right Questions Depends on your Situation New facility Single product Development Biological product CMO Few kg per year Established facility Multi product Commercial production Chemical product Innovators' Facilities Ton of product per year
12 A through understanding of product and process risks are required in order to have a robust process with demonstrated patient safety, and product availability The Pyramid represents the desired state results of any well executed Single Use System implementation
13 A well designed Manufacturing Strategy including Process Control, and Logistic Controls supports the desired state: product and process knowledge, patient safety, and product availability 13
14 The outer circle identifies individual strategies required to successfully met the desired state 14
15 Organization of the Document 15
16 16
17 Supply Qualification Transportation Guided Decision Process 17 Regulatory acceptance System reliability Internal change acceptance Process validation Measurement quality Process interaction Size, Pressure, Temperature Limitations Complexity of the system Compatibility Flexibility Facility utilization Balance of capital and operating costs Cross contamination Adsorption Extractables/Leachables System Integrity Loss Process adjustments Operator Safety Risk Management Tools Knowledge Management Tools
18 Guided Decision Process - 1
19 Guided Decision Process - 2
20 Guided Decision Process - 3
21 Guided Decision Process - 4 If the answer is YES to all question, then implementation of SUS can only be too SLOW
22 Your Situation Determines the Right Answers! Activities focused on core functions Enables You Business Model and Goals Supports Product Development Stage SUS solves a problem: Improves Flexibility, Containment! Reduces Cross Contamination or Cost! 22
23 Supply Qualification Transportation Manufacturing Strategy 23 Regulatory acceptance System reliability Internal change acceptance Process validation Measurement quality Process interaction Size, Pressure, Temperature Limitations Complexity of the system Compatibility Flexibility Facility utilization Balance of capital and operating costs Cross contamination Adsorption Extractables/Leachables System Integrity Loss Process adjustments Operator Safety Risk Management Tools Knowledge Management Tools
24
25
26 Is a SUS Solution Technically Feasible Structured evaluation of the available technical solutions Comparing MUS and SUS solutions Moving to more and more intergraded / complex systems Technical risk evaluation Integration between: MUS and SUS SUS and SUS Different suppliers Fitting into the facility 26
27
28 Is SUS Good Business Balance on fixed and operating costs Time to marked Number of products / batches per year Green manufacturing - Waste handling Risk factors productions failures, contaminations, supplier delivery issues, cleaning validation Facility utilization / flexibility different product / locations Time to establish manufacturing facility 28
29
30 Patient Safety Can Never be Compromised Extractables and Leachables issues Risk evaluation balancing pro and cons for MUS and SUS systems Sanitation and sterilization Integrity testing Quality of components / data from SUS sensors Supplier Audits / Qualification Validation issues Acceptance test installation qualification 30
31 Application Risk A Directional Risk Profile of SUS Applications System complexity Low Medium High High Freeze thaw Fill and finish Medium Transport shipping Mixing Low Buffer storage Concentration Cell culture Product storage Purification Clarification Recovery The addition of valves, sensors and manifolds increases complexity and risk 31
32
33 Key Elements for Project Success Risk Assessment logistic issues and combining risk assessments from the other sections to the full picture Full implementation plan Stakeholder Management Supplier agreements Training Safety for operators Material management receiving, storage, transport and waste Facility layout 33
34 Voice of the PDA Community 10 topic blocks Quality Regulatory Implementation Business Supplier Relation Risk Assessment 34
35 Voice of the PDA Community 1. What have been the biggest road blocks for implementing SUS within your organization? Why were these roadblocks difficult to overcome? What would enable success in future implementation projects? Lack of experience Fear of unknown No clear roadmap Many venders to deal with Plastics integrity and quality issues How to validate SUS 35
36 Asking the Right Questions How do I use QRM as a guideline for decisions? How does this differ from what I am doing today? What do I need to learn/buy/train/change? How will this change the way I operate and impact my business systems? What do I need to be thinking about as I scale up? How do I introduce SUS in my current products stainless-based systems? Are SUS part of a sustainable Green Manufacturing strategy? What is the process for SUS component selection? Will SUS be a Supply Chain Risk? Are SUS cost effective, or will they increase my cost of goods? 36
37 Time line for the SUS TR Summer 2008 Task Force established Autumn 2010 First Draft Finalized Spring 2011 Editing and Internal review June PDA SUS Work Shop Summer 2011 External Review 4Q/ 2011 Publish Document 37
38 Special Thanks to members of the Single System Task Force and their sponsor organizations 38
Industry Proposal for Implementation of Single-Use User Requirements (SUUR) Toolkit. Joint BioPhorum / BPSA Team
Industry Proposal for Implementation of Single-Use User Requirements (SUUR) Toolkit Joint BioPhorum / BPSA Team Introduction Problem Statement implementation of single-use systems in GMP operations frequently
More informationFocused pharma engineering
Focused pharma engineering When change is the only constant, are you up to speed? Welcome to the new pharma reality A major shift has taken place in the world of pharma manufacturing. The days when delivering
More informationAdvancements on implementation of single use technology in vaccine manufacturing
Advancements on implementation of single use technology in vaccine manufacturing October 25 th, 2013 DCVMN Meeting Rio de Janeiro, Brazil Outline Overview of single use products Applications of single
More informationCalendar. The Clear Solution to Reach the Global Biopharma Audience. INTERNATIONAL
The Clear Solution to Reach the Global Biopharma Audience yvdavyd/getty Images & blackred/e+/getty Images 2017 EDITOrial Calendar Editorial Coverage Special Themed Issues January Biopharma Outlook for
More informationSingle-Use Products in BioManufacturing: Innovations Driving the Industry Bioprocess International SUPPLEMENT March 2011 By Eric Langer
Single-Use Products in BioManufacturing: Innovations Driving the Industry Bioprocess International SUPPLEMENT March 2011 By Eric Langer Biopharmaceutical manufacturers and CMOs are continuing to integrate
More informationParadigm Change in Manufacturing Operations
Technical Report No. 54-4 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 3: Case Studies in the Manufacturing of Biotechnological Bulk Drug
More informationDevelopment from Bench to Clinic
Accelerating Novel Vaccine Development from Bench to Clinic Roger Lias. Ph.D. President Eden Biodesign, Inc Questions Questions are encouraged and can be asked by sending an email to: edenbiodesign@propelmg.com
More informationShow Me the Green! A Value Plastics White Paper
Value Plastics, inc. SPECIALISTS IN FLUID CONNECTIONS TM Single-Use Systems Show Me the Green! A Value Plastics White Paper Value Plastics, inc. SPECIALISTS IN FLUID CONNECTIONS TM Single-Use Systems Show
More informationBiopharmaceutical Multi-Product Facilities: the Challenges and the Solutions. Frank Hallinan EBE Biopharmaceutical Manufacturing & CMC Conference
Biopharmaceutical Multi-Product Facilities: the Challenges and the Solutions. Frank Hallinan EBE Biopharmaceutical Manufacturing & CMC Conference Barcelona, March 21, 2011 Agenda: The Past The Business
More informationGo strategic with single-use technologies FEBRUARY 2017
Go strategic with single-use technologies FEBRUARY 2017 NEW PHARMA REALITY The world of pharmaceutical manufacturing is changing dramatically The pharma and biotech industry is booming with large and diverse
More informationSingle-use bioprocess
B I O P R O C E S S TECHNICAL Guide to Irradiation and Sterilization Validation of Single-Use Bioprocess Systems, Part 2 The Irradiation and Sterilization Subcommittee of the Bio-Process Systems Alliance
More informationSingle-Use Final Fill: Benefits and Considerations
Single-Use Final Fill: Benefits and Considerations TENDÊNCIAS DE TECNOLOGIAS DE FABRICAÇÃO E ASSÉPTICA DE MEDICAMENTOS Ana Luísa Lampert Cadore Sales Specialist SU & Aseptic Process Solutions ana.cadore@merckgroup.com
More informationPreview of New PDA Technical Report on Process Validation
PCMO (Paradigm Change to Manufacturing Operations) Process Validation and Verification: A Life- cycle Approach Preview of New PDA Technical Report on Process Validation Peter Levy PL Consulting, LLC peter@plevyconsulting.com
More informationTransition to Next Gen Downstream Processing to Capitalize on Growth Opportunities in High-Value Low-Volume Biologics
A Virtual Think Tank Executive Summary Transition to Next Gen Downstream Processing to Capitalize on Growth Opportunities in High-Value Low-Volume Biologics By: Unmesh Lal, Program Manager, Transformational
More informationTechnical Report No. 60 Process Validation: A Lifecycle Approach
Technical Report No. 60 Process Validation: A Lifecycle Approach Paradigm Change in Manufacturing Operations SM PDA Task Force on Technical Report No. 60: Process Validation: A Lifecycle Approach Authors
More information2016 Editorial. Advancing Development & Manufacturing. Calendar w w w. P h a r m Te c h. c o m. Editorial coverage
Advancing Development & Manufacturing 2016 Editorial Calendar w w w. P h a r m Te c h. c o m COMPlete Editorial coverage EDITORIAL COVERAGE: EXPERT INSIGHT AND ANALYSIS Pharmaceutical Technology continues
More informationDivision of Docket Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
October 3, 2008 PDA Global Headquarters Bethesda Towers 4350 East West Highway Suite 200 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org OFFICERS Chair: John Shabushnig,
More informationCC: Richard Levy, PDA; Denyse Baker, PDA
Bethesda Towers 4350 East West Highway Suite 150 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org OFFICERS Chair Harold Baseman ValSource Chair-Elect Martin VanTrieste Amgen
More informationAspiring to Measure Quality Culture
Aspiring to Measure Quality Culture Denyse Baker PDA Director of Science and Regulatory Affairs Pharmaceutical Quality Congress The Unintended Consequences of Quality June 14-16, 2017 - Bethesda, MD 1
More informationExtractables and Leachables in Early Phase Development
Extractables and Leachables in Early Phase Development Wayland Rushing, Ph.D. Senior Scientific Advisor, ABC 11/23/2015 Product and Process Variants & Impurities 1 Regulatory Perspective Dr. Ingrid Markovic,
More informationAdvancing Development & Manufacturing. On target. On topic EDITORIAL CALENDAR.
Advancing & On target. On topic. EDITORIAL CALENDAR EDITORIAL COVERAGE: EXPERT INSIGHT AND ANALYSIS Pharmaceutical Technology sets the standard for publishing independent, industry-leading information
More informationBiopharmaceutical Manufacturing Systems
PharmaED s D Register by August 1 st and receive a $300 isposable & Single-Use Discount! Biopharmaceutical Manufacturing Systems Understanding the Advantages, Costs, Regulatory and Process Considerations
More informationThe Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager
The Application of Pharmaceutical cgmp to Live Bacterial Products James Harris Business Development Manager The Objective CMC expectations of a cgmp live bacterial biopharmaceutical project Overview Define
More informationQuality & Regulatory Issues in Biopharmaceutical Facility Design A Perspective from Industry Trends
Quality & Regulatory Issues in Biopharmaceutical Facility Design A Perspective from Industry Trends Paul Smock, Biotechnology Quality & Technical Consultant Meridian BioGroup LLC The opinions and views
More informationCurrent Trends in Single Use Technologies: Future Developments Affecting Production
5 September 2016 Current Trends in Single Use Technologies: Future Developments Affecting Production Eric S. Langer President and Managing Partner, BioPlan Associates, Inc. 2275 Research Blvd, Suite 500
More informationProduct Protection Control Strategies for Non-Sterile Drug Substance Manufacturing
Protection Control Strategies for Non-Sterile Drug Substance Manufacturing Michael Hendershot, Research Scientist Technical Services / Manufacturing Sciences Eli Lilly & Company Contents Purpose of a Protection
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationIntensification of a Perfusion Platform using Single-use XCell ATF Systems
Intensification of a Perfusion Platform using Single-use XCell ATF Systems Olaf Mol Sr. Bioprocess Scientist The world leader in serving science Global Footprint- Biologics Princeton, USA PD Center of
More informationNew technologies in biopharmaceutical processes BioTech Vaccines Plasma
New technologies in biopharmaceutical processes BioTech Vaccines Plasma Dominik Arnold dominik_arnold@pall.com Challenges in Down Stream Processing Higher. Titers >4 g/l Yield > 90% Protein concentration
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationCSL s Large Scale Cell Culture Facility
BioProcess Network 20 th October 2011 CSL s Large Scale Cell Culture Facility Tim Hughes Sr. Dir. Clinical Manufacturing CSL Objective How to maximise the opportunity to build a state-of-theart facility
More informationWednesday, June 13. 7:00 a.m. 5:30 p.m. Registration Open 7:00 a.m. 8:30 a.m. Continental Breakfast
Wednesday, June 13 7:00 a.m. 5:30 p.m. Registration Open 7:00 a.m. 8:30 a.m. Continental Breakfast 2018 PDA Container Closure Performance and Integrity Conference Assuring Packaging Quality in Delivery
More informationConsiderations for establishing a single use technology-based biological plant: Case Study
Considerations for establishing a single use technology-based biological plant: Case Study PDA Israel Single Use Equipment Tel Aviv, 7th May 2018 Nitzan Levy, Ph.D Tarom Applied Technologies The Israeli
More informationThe Use of BPOG Generated Extractables Data for Toxicological Assessment
The Use of BPOG Generated Extractables Data for Toxicological Assessment Sade Mokuolu, Ph.D Group Product Compliance Manager, WMFTG PDA Brazil 2017 Disclaimer This presentation is the copyright information
More informationTechnical Report No. 61 Steam In Place
Technical Report No. 61 Steam In Place PDA Technical Report No. 61: Steam in Place Task Force Members Authors Kevin Trupp (Task Force Chair), Retired Dave Adams, Baxter Healthcare Corporation Keith E.
More informationRecent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca
Recent Developments & Future Directions in the Production of Monoclonal Antibodies Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Forecast sales by molecule type ($m), 2006 12 600,000 Pharmaceuticals
More informationThe expanding complexity of
A Vaccine Case Study Qualifying Redundant Disconnection Technologies As Container-Closure Systems for Long-Term Storage and Shipping Christine Megarity and Bobbi Allen The expanding complexity of biopharmaceutical
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationTowards Flexible Single-use Biomanufacturing: Key Technologies Needed and Lessons Learned
Case studies in process intensification Towards Flexible Single-use Biomanufacturing: Key Technologies Needed and Lessons Learned March 14, 2017 San Diego, California Adam Goldstein, Oliver Molina, Michelle
More informationContinuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities
Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities Erik Fouts, Ph.D. VP and Site Head, Novato Operations 3-4 December ASTM E2968 14 Continuous
More informationCase study-cmc challenges when a small biosimilar developer must rely on outsourcing for development and manufacturing
CMC Workshop April 24-26, 2017 Case study-cmc challenges when a small biosimilar developer must rely on outsourcing for development and manufacturing Patricia Seymour Session 07B 1 Disclaimer The views
More informationProcess economic simulation for scalable production of adenovirus
Process economic simulation for scalable production of adenovirus This application note discloses process economic modelling of a modern start-to-finish adenovirus production process. The novel process
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationQuality by Design in Critical Filtration Operations
Quality by Design in Critical Filtration Operations Michael Payne Senior Biosafety Technical Consultant Yanglin Mok Technical Manager Objectives Define quality by design (QbD) and Quality Risk Management
More informationParadigm Change in Manufacturing Operations SM
Technical Report No. 54-2 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 1: Case Study Examples for Quality Risk Management in Packaging and
More informationProcess Validation Lifecycle Approach: A Return to Science
Process Validation Lifecycle Approach: A Return to Science Hal Baseman, ValSource LLC, PDA Chairman PDA & ISPE Joint New England Chapter Process Validation Event Sep 16, 2015 Woburn, MA Program Summary
More informationRisk Management in Drug Product Manufacturing with Emphasis on Batch Documentation/Execution
Risk Management in Drug Product Manufacturing with Emphasis on Batch Documentation/Execution Manufacturing Breakout Session I Jack Pellett (Genentech) and Eleni Dokou (Vertex) What are typical lead-times
More informationAn Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America
An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America SPEAKERS: Janett Mugaburu-Richards, M.S. Pfizer Inc. Kavita Ramalingam Iyer, Ph.D Merck & Co., Inc. Contents
More informationThe State of QbD in the Biopharmaceutical Industry Conference
The State of QbD in the Biopharmaceutical Industry Conference Criticality Assessment, Design Space Implementation and Control 10 11 April 2013 Sheraton Fisherman s Wharf San Francisco, California USA Sponsored
More informationRegulatory Affairs & Quality Advisory Board. A Parenteral Drug Association (PDA) Advisory Board
Regulatory Affairs & Quality Advisory Board A Parenteral Drug Association (PDA) Advisory Board Purpose of Presentation RAQAB has a goal of improving communication of RAQAB activities to the membership
More informationABL Europe s GMP manufacturing facility for viral vector production
ABL Europe s GMP manufacturing facility for viral vector production New Production Capacity for Viral Vectors Success Story ABL Europe GMP manufacturing of viral vectors from non-adherent cell cultures
More information2018 EDITORIAL COVERAGE. Connecting the Pharma Industry for 28 Years.
2018 EDITORIAL COVERAGE Connecting the Pharma Industry for 28 Years EDITORIAL COVERAGE: EXPERT INSIGHT AND ANALYSIS Pharmaceutical Technology Europe sets the standard for publishing independent, industry-leading
More information9/28/2018 FLEXIBILITY BY DESIGN. Morten Munk ISPE Product Show Track 2, Session 5 September 26, 2018 TRENDS A LITTLE QUIZ
FLEXIBILITY BY DESIGN Morten Munk ISPE Product Show Track 2, Session 5 September 26, 2018 TRENDS A LITTLE QUIZ 2 1 Trends Multi product - flexible facilities Hybrid facilities 2-8 times 15K SS 2-8 times
More informationBavarian Nordic A/S was
S I N G L E - U S E IMPLEMENTATION Rapid Implementation of a Smallpox Vaccine Facility A Case Study in Single-Use Technology Karin Wassard and Miriam Monge Bavarian Nordic A/S was founded in 1994 and listed
More informationCMC Activities for Commercialization: PAI, QMS, and BLA/NDA. NEPDA Dinner Meeting Cambridge, MA 16 May 2018
CMC Activities for Commercialization: PAI, QMS, and BLA/NDA Advancing from Clinical to Commercial The Commercialization Roadmap NEPDA Dinner Meeting Cambridge, MA 16 May 2018 Standards Certification Education
More informationConnecting People, Science and Regulation
Connecting People, Science and Regulation Bethesda Towers 4350 East West Highway, Ste 600 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org PDA Europe ggmbh Am Borsigturm
More informationWelcome to the WCBP CMC Strategy Forum
Welcome to the WCBP CMC Strategy Forum We are pleased to welcome you to the 24 th WCBP CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product
More informationMeeting temperature requirements in a changing environment
Meeting temperature requirements in a changing environment After an extremely successful launch in 2017 and great growth for the 2018 edition, Temperature Controlled Logistics in Biopharmaceuticals will
More informationFlexboy 2D Pre-designed Solutions for Storage Best Performance, Assurance of Supply and Closure Integrity for All Process Steps
Storage Best Performance, Assurance of Supply and Closure Integrity for All Process Steps 2 Flexboy 2D Pre-designed Solutions Table Please click on the headline to go to the selected topic Digital Selection
More informationPDA Bioburden and Biofilm Workshop
The Parenteral Drug Association presents the... PDA Bioburden and Biofilm Workshop Controlling Microbial Contamination to Assure Product Quality, Patient Safety Save $100 when you register for the workshop
More information3rd Annual Global Drug Bioavailability Enhancement Summit
3rd Annual Global Drug Bioavailability Enhancement Summit Event Summary Most drugs on today s market display poor solubility, but the use of modern solubilization technologies can improve a drug product
More informationHigh Potent Medicines Conference
2nd Annual High Potent Medicines Conference Looking beyond scale-up, containment, regulatory aspects and safety of highly potent compounds Event Overview The HPAPI industry is expanding at a healthy rate
More informationSingle-use technology in downstream unit operations
Single-use technology in downstream unit operations ÄKTA ready chromatography system and more Madhu Raghunathan, Bioprocess capability days, Boston Imagination at work Presentation outline Introduction
More informationWhile attending a conference
B I OP ROCESS INTERVIEW Total Solutions Support the Growth of a Dynamic Industry A Conversation with Reinhard Vogt and Stefan Schlack by Brian Caine and S. Anne Montgomery While attending a conference
More informationTechnical Report No. 48 Moist Heat Sterilizer Systems: Design, Commissioning, Operation, Qualification and Maintenance
Technical Report No. 48 Moist Heat Sterilizer Systems: Design, Commissioning, Operation, Qualification and Maintenance 2010 Moist Heat Sterilizer Systems: Design, Commissioning, Operation, Qualification
More informationWednesday, June 13. 7:00 a.m. 5:30 p.m. Registration Open 7:00 a.m. 8:30 a.m. Continental Breakfast
Wednesday, June 13 7:00 a.m. 5:30 p.m. Registration Open 7:00 a.m. 8:30 a.m. Continental Breakfast 2018 PDA Container Closure Performance and Integrity Conference Assuring Packaging Quality in Delivery
More informationCurrent speakers: November 27 th 28 th 2018 Burlingame, USA
3 rd Annual Pharma and Device Packaging and Labeling West Coast Conference Bringing industry professionals to create streamlined operations within product packaging and labelling. November 27 th 28 th
More informationAgenda. Pharma EXPO 6 9 November 2016 Chicago, IL FLEXIBLE FACILITIES THE BENEFITS OF MODULAR AND PREFABRICATED CLEANROOM STRUCTURES
FLEXIBLE FACILITIES THE BENEFITS OF MODULAR AND PREFABRICATED CLEANROOM STRUCTURES Maik W. Jornitz President G-CON Manufacturing Inc. Agenda Hot Button Headlines Future Needs The Past does not Fit The
More informationThe biopharmaceutical industry
S i n g l e - U s e APPLICATIONS Understanding Particulates in Single-Use Bags Their Relationship to USP Chapter by Michael W. Johnson The biopharmaceutical industry is facing many challenges. Global
More informationFinding Fakes. Not all counterfeits are so easy to spot or so harmless. Upfront How to make existing drugs more biodegradable
OCTOB E R 201 5 # Upfront How to make existing drugs more biodegradable In My View Is it time for no biomarker, no trial? Best Practice Taking on the challenges of personalized cell therapies Business
More informationCMC Consideration for the Development of Regenerative Medical Products
CMC Strategy Forum Japan 2018 December 4, 2018, Tokyo Marriot Hotel, Tokyo, Japan CMC Consideration for the Development of Regenerative Medical Products Kazunobu Oyama, PhD Deputy Review Director, Office
More informationFacility of the Future: Next Generation Biomanufacturing Forum
Reprinted from PHARMACEUTICAL ENGINEERING THE OFFICIAL TECHNICAL MAGAZINE OF ISPE MAY/JUNE 2013, VOL 33, NO 3 Copyright ISPE 2013 www.pharmaceuticalengineering.org facilities and equipment Facility of
More informationHigh Potent Medicines Conference
2nd Annual 2nd Annual MARKETS MARKETSand andmarkets MARKETS High Potent Medicines Conference scale-up, containment, regulatory aspects and safety Main Looking Taunusbeyond Zentrum, Frankfurt, Germany of
More informationManaging QbD From A CMO Perspective
Managing QbD From A CMO Perspective By Cathy Yarbrough The concepts and methods of Quality by Design (QbD), which the automobile, airline, and electronics industries have utilized to enhance the quality
More informationBiopharmaceuticals A Regulatory Perspective
Biopharmaceuticals A Regulatory Perspective Maeve Lally Senior Pharmaceutical Assessor (Biologics) CASSS CMC Forum Killarney May 2017 Cead Mile Fáilte A hundred thousand welcomes 26/06/2017 2 Disclaimer
More informationFEBRUARY 2017 YOUR FACILITY: FROM CONCEPT TO FIRST MARKET BATCH. AND BEYOND.
Bio on demand TM achieve agile and flexible operations FEBRUARY 2017 YOUR FACILITY: FROM CONCEPT TO FIRST MARKET BATCH. AND BEYOND. NEW PHARMA REALITY The world of pharmaceutical manufacturing is changing
More informationTim Moore Global Head, Pharmaceutical Technical Operations Biologics, Genentech a member of the Roche Group
Ensuring the Supply of Quality Biopharmaceuticals: Integrated Manufacturing Network & Continual Improvement of Manufacturing Process Tim Moore Global Head, Pharmaceutical Technical Operations Biologics,
More informationGlobal Bio Conference 2017 Seoul, Korea 30 June Contract Manufacturing An Experience from Germany and Malaysia A Case Study.
Global Bio Conference 2017 Seoul, Korea 30 June 2017 Contract Manufacturing An Experience from Germany and Malaysia A Case Study History Pioneering Recombinant Biopharmaceuticals Road to Success In 1986
More informationAn Introduction to Double Dragon Consulting
An Introduction to Double Dragon Consulting www.doubledragonconsulting.com About DDC Our Experience: - All dosage forms, aseptic processes, API manufacture, OTC - Remediation of 483 observations, Warning
More informationDear Colleagues, Looking forward to seeing you in Singapore, Andiyanto Sutandar, Technical Director, HGP Asia Pte. Ltd.
2018 PDA Annual Singapore Conference New Developments in Bio/Pharmaceutical Manufacturing and Regulation October 30-31, 2018 Westin Singapore Singapore, Singapore Dear Colleagues, The 2018 PDA Annual Singapore
More informationApril 9, Dear Sir/Madam,
Bethesda Towers 4350 East West Highway Suite 150 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org OFFICERS Chair Harold Baseman ValSource Chair-Elect Martin VanTrieste Amgen
More informationThe Opta SFT-D is available as individual device for end-user assembly with TPE tubing and autoclave sterilization.
Fluid Management 259 Connections 260 Flexboy Bags 264 Flexel 3D Bags 276 Palletank 304 Instruments 314 Single-Use Mixing 318 Freeze-Thaw Systems 354 Aseptic Transfer System 380 Configurable Solutions FlexAct
More informationMDI Manufacturing Services
MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products
More informationDeveloping a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods
Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods Single-use systems (SUS) offer biopharmaceutical manufacturers significant gains in process flexibility,
More informationFacility of the Future: Next Generation Biomanufacturing Forum
Reprinted from PHARMACEUTICAL ENGINEERING The Official Technical Magazine of ISPE March/April 2013, Vol 33, No 2 Copyright ISPE 2013 www.pharmaceuticalengineering.org facilities and equipment Facility
More informationValidation Needs for Sterilization by Aseptic Filtration
Validation Needs for Sterilization by Aseptic Filtration DCVMN Workshop, Hyderabad, 4-8 April 2016 Ramesh Raju Associate Director - Provantage Validation Services Overview Key Regulatory and Industry guidelines
More informationA Look into the Future of Bioprocessing by Dr. Svea Grieb, Kai Touw and Dan Kopec
A Look into the Future of Bioing by Dr. Svea Grieb, Kai Touw and Dan Kopec The internet of things and robotics are already the working standard in fastadapting industries. These technologies are now also
More informationPatients are Counting on Us: It s Time to Act
Patients are Counting on Us: It s Time to Act Brian Johnson Chairman Rx-360 Senior Director Supply Chain Security Pfizer, Inc. 24 th Global GS1 Healthcare Conference October 2, 2013 THE WALL STREET JOURNAL
More informationCurrent speakers: November 27 th 28 th 2018 Burlingame, USA
3 rd Annual Pharma and Device Packaging and Labeling West Coast Conference Bringing industry professionals to create streamlined operations within product packaging and labelling. November 27 th 28 th
More informationProcess Transfer Excellence Basis for a fast and successful project
Process Transfer Excellence Basis for a fast and successful project Dr. Stefan Minning, Dr. Lars Dreesmann Boehringer Ingelheim Pharma GmbH & Co. KG Excellence in Biopharmaceutical Process Transfer Boehringer
More informationSingle-use bioprocess
FOCUS ON... STANDARDS Guide to Irradiation and Sterilization Validation of Single- Use Bioprocess Systems, Part 1 The Irradiation and Sterilization Subcommittee of the Bio-Process Systems Alliance Single-use
More informationGE Healthcare s cell culture media, sera and process liquids
GE Healthcare s cell culture media, sera and process liquids upstream downstream single-use Global operational footprint Imagination at work. www.gelifesciences.com/hyclone services GE Healthcare BioProcess
More informationinnovation regulation commercialization 2018 BPSA SINGLE-USE SUMMIT From Evolution to Revolution: How SUTs Accelerate Life-Saving Therapies
2018 BPSA SINGLE-USE SUMMIT From Evolution to Revolution: How SUTs Accelerate Life-Saving Therapies innovation regulation commercialization JULY 9 11, 2018 WASHINGTON, DC FOUR SEASONS HOTEL AGENDA > SPEAKERS
More informationOverview Rentschler Biotechnologie
Overview Rentschler Biotechnologie AusBiotech, Adelaide, 18.10.2011 Klaus B. Schoepe, PhD, SVP Client Relations - 1 - Our Mission As an independent leading, internationally operating service company, we
More informationTom Sulpizio and Jeff Taniguchi, Advanced Minerals Corporation A Member of Imerys 130 Castilian Way, Santa Barbara, CA 93117
ADVANCES IN DISPOSABLE DIATOMITE FILTER AID SYSTEMS FOR CGMP BIOSEPARATIONS Session Pretreatment in Bioseparations AFSS Annual Meeting Valley Forge, PA May 20, 2008 ABSTRACT Tom Sulpizio and Jeff Taniguchi,
More informationA GUIDE TO BIOMANUFACTURING AT GENZYME
M A K I N G P R O T E I N T H E R A P I E S A GUIDE TO BIOMANUFACTURING AT GENZYME Genzyme strives to make a life-changing difference for patients with serious diseases by discovering, developing, and
More informationEuropean Medicines Agency Quality Working Party, London
Europe ggmbh Adalbertstraße 9 16548 Glienicke/Berlin Germany Tel: +49 (33056) 2377-10 Fax : +49 (33056) 2377-77 Georg Roessling, PhD General Manager Senior Vice President PDA Europe http://europe.pda.org
More informationVia Electronic Mail. European Medicines Agency (EMEA) London
Via Electronic Mail 14 March 2008 PDA Europe Managing Director & Sr. VP Georg Roessling, PhD Adalbertstr. 9 16548 Glienicke/ Berlin Germany Tel: + 49 33056 2377-10 Fax: + 49 33056 2377-77 Email: info-europe@pda.org
More informationNorthern California Regional Forum
Northern California Regional Forum Cell and Gene Therapies South San Francisco Conference Center South San Francisco, CA Thursday, November 8, 2018 Co-chairs: Nomalie Jaya, Seattle Genetics, Inc. David
More information